NCT00109252

CompletedPhase 3

A Study to Evaluate Raptiva in Adults With Plaque Psoriasis ...

Genentech, Inc.Source

Compare

Other study identifiers

Sponsor study identifier

ACD2391g

Study Type

interventional

Reported enrollment (type unavailable)

0

Locations

0 countries

Sites

N/A

Timeline

Study Start

January 2002

Date type not reported

This date has not been verified as actual or estimated.

Primary Completion

Not reported

Date not reported

Study Completion

April 2003

Actual (reported)

Brief Summary

This is an open-label, multicenter study designed to evaluate the efficacy and safety of efalizumab administered at weekly SC (subcutaneous) doses of 1.0 mg/kg followed by efalizumab taper in subjects with plaque psoriasis who previously participated in Study ACD2390g.

Registry Overview

Registry-reported information. Elapsed time and enrollment totals alone do not measure study progress or recruitment pace.

Recruitment status: completed
Reported enrollment (type unavailable): 0 participants
Study completion date: April 2003
Actual (reported)
Listed locations: 0 countries · 0 sites

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Dates and qualifiers reported by the registry. Estimated dates do not confirm that a milestone has occurred.

Study Start
January 2002
Date type not reported
This date has not been verified as actual or estimated.
Study Completion
April 2003
Actual (reported)
First Submitted
April 26, 2005
Actual (reported)
First Posted
April 26, 2005
Actual (reported)

Last Updated: June 21, 2013
Status Verified: June 2013
Last Update Submitted: June 19, 2013

Conditions

Psoriasis

Keywords

Plaque PsoriasisTopical

Interventions

Raptiva (efalizumab)Drug

Eligibility Criteria

Sexall

Healthy VolunteersNo

Age GroupsChild (0-17), Adult (18-64), Older Adult (65+)

You may qualify if:

Signed informed consent
Previous participation in Study ACD2390g

Sponsors & Collaborators

Genentech, Inc.
Industrylead

MeSH Terms

Conditions

Psoriasis

Interventions

efalizumab

Condition Hierarchy (Ancestors)

Skin Diseases, PapulosquamousSkin DiseasesSkin and Connective Tissue Diseases

Study Design

Study Type: interventional
Phase: phase 3
Masking: NONE
Purpose: TREATMENT
Sponsor Type: INDUSTRY
Responsible Party: SPONSOR

Study Record Dates

First Submitted

April 26, 2005

First Posted

April 26, 2005

Study Start

January 2002

Date type not reported

This date has not been verified as actual or estimated.

Study Completion

April 2003

Actual (reported)

Completed

NCT00096980

A Study to Evaluate Raptiva in Combination With Topical Psoriasis Therapies

Phase 4Completed

NCT00312026

A Study to Evaluate the Safety and Efficacy of Efalizumab in Adult Patients With Plaque Psoriasis Involving the Hands and/or Feet

Phase 4Completed

NCT00669214

A Study to Evaluate the Safety and Efficacy of Efalizumab in Adult Patients With Moderate to Severe Plaque Psoriasis With Involvement of the Scalp

Phase 4Completed

NCT00336973

A Study to Evaluate Raptiva in Subjects With Chronic Moderate or Worse Plaque Psoriasis Who Have Had an Inadequate Response to an Anti-TNF Agent

Phase 4Completed

NCT00111436

Evaluating the Safety of Etanercept in the Treatment of Psoriasis in Adult Subjects

Phase 3Completed

NCT00106834

A Study of the Safety and Efficacy of Infliximab in Patients With Psoriasis

Phase 3Completed

For women of childbearing potential, continued use of an acceptable method of contraception for the duration of their participation in the study

Willingness to continue to hold sun exposure reasonably constant and to avoid use of tanning booths or other UV light sources throughout the study

You may not qualify if:

Any medical condition that, in the judgment of the investigator, would jeopardize the subject's safety following exposure to efalizumab
Systemic therapy for psoriasis (ET Day 0 through FU Day 84 or upon relapse or unusual presentation of psoriasis in the FU period, whichever occurs first)
Systemic immunosuppressive drugs for other indications (ET Day 0 through FU Day 84)
Topical therapies for psoriasis (ET Day 0 through ET Day 84)
Live virus or bacteria vaccines (ET Day 0 through FU Day 84)
Other vaccines or allergy desensitization (it is recommended that these be scheduled after FU Day 84)
Other experimental drugs or treatments (ET Day 0 through FU Day 84)
Beta-Blockers, ACE inhibitors, interferons, quinidine, antimalarial drugs, or lithium (if clinically indicated, such medications are allowed but the dosage should be held constant between ET Day 0 and TT Day 84)

Contact the study team to confirm eligibility.

Last Updated

June 21, 2013

Record last verified: 2013-06

Source record

Download the complete ClinicalTrials.gov record imported by Syfrah, including fields not shown in this page. The registry may contain a newer revision.

Source: ClinicalTrials.gov.

JSON downloads include source attribution and retrieval details alongside the unchanged original record or the separately normalized values.

Registry identifier: NCT00109252
Data provider: ClinicalTrials.gov
Source updated: 2013-06-21
Normalization version: ctgov-legacy-1

Open registry record

Source retrieved: 2026-10-25 22:30:38 UTC

Brief Summary

Registry Overview

Trial Relationships

Related Scientific Literature

Study Timeline

Study Start

Study Completion

First Submitted

First Posted

Conditions

Keywords

Interventions

Eligibility Criteria

You may qualify if:

Sponsors & Collaborators

MeSH Terms

Conditions

Interventions

Condition Hierarchy (Ancestors)

Study Design

Study Record Dates

You may not qualify if:

Source record